Foundations of Transplant · 3 min read
Overview of Hematopoietic Stem Cell Transplantation · Types of Transplantation · Stem Cell Sources
Hematopoietic stem cell transplantation (HSCT) is a procedure that replaces damaged or diseased bone marrow with healthy hematopoietic stem cells. These pluripotent cells can differentiate into all blood cell lineages including erythrocytes, leukocytes, and platelets. HSCT serves as a curative or life-prolonging treatment for various malignant and non-malignant hematologic disorders.
The history of transplantation dates to the mid-twentieth century when researchers discovered that bone marrow infusion could reconstitute hematopoiesis following lethal irradiation. The first successful allogeneic transplant occurred in 1968 for a patient with severe combined immunodeficiency. Since then, advances in conditioning regimens, supportive care, and donor matching have dramatically improved outcomes.
Transplant indications continue to expand. Common malignant indications include acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, multiple myeloma, Hodgkin lymphoma, and non-Hodgkin lymphoma. Non-malignant conditions treated with HSCT include aplastic anemia, sickle cell disease, thalassemia major, severe combined immunodeficiency, and inherited metabolic disorders.
Transplants are classified by donor source and stem cell origin. Understanding these distinctions is fundamental to BMT nursing practice.
Autologous Transplantation
Autologous transplant uses the patient's own stem cells collected before high-dose therapy. The patient serves as both donor and recipient. This approach eliminates graft-versus-host disease risk and does not require HLA matching. However, autologous transplant lacks the graft-versus-tumor effect that contributes to disease control in allogeneic transplant.
Primary indications for autologous transplant include multiple myeloma, relapsed Hodgkin lymphoma, relapsed non-Hodgkin lymphoma, and certain solid tumors such as neuroblastoma and germ cell tumors. The procedure involves stem cell mobilization, collection via apheresis, cryopreservation, administration of high-dose conditioning chemotherapy, and reinfusion of thawed stem cells.
Allogeneic Transplantation
Allogeneic transplant uses stem cells from a genetically different donor. The donor may be a matched related donor (typically an HLA-identical sibling), matched unrelated donor identified through registries, haploidentical related donor sharing half the HLA antigens, or umbilical cord blood unit.
Allogeneic transplant provides both hematopoietic rescue and immunologic graft-versus-tumor effect. However, it carries risks of graft-versus-host disease, graft failure, and prolonged immunosuppression. Allogeneic transplant is indicated for diseases requiring immune-mediated disease control or replacement of defective marrow.
Syngeneic Transplantation
Syngeneic transplant uses stem cells from an identical twin. This rare scenario provides genetically identical cells without GVHD risk but also without graft-versus-tumor effect. Syngeneic transplant is functionally similar to autologous transplant regarding immunologic considerations.
Hematopoietic stem cells can be obtained from bone marrow, peripheral blood, or umbilical cord blood. Each source has distinct characteristics affecting engraftment, GVHD risk, and clinical outcomes.
Bone Marrow
Bone marrow harvest involves surgical aspiration from posterior iliac crests under general or regional anesthesia. The procedure yields approximately 10-20 mL/kg recipient weight of marrow containing 2-4 × 10^8 nucleated cells per kilogram. Bone marrow grafts contain fewer T cells than peripheral blood grafts, potentially reducing chronic GVHD risk.
Donor risks include anesthesia complications, pain at harvest sites, fatigue, and rarely infection or nerve injury. Most donors recover fully within two to four weeks. Bone marrow remains preferred for certain non-malignant conditions and pediatric donors.
Peripheral Blood Stem Cells
Peripheral blood stem cell (PBSC) collection requires mobilization of stem cells from marrow into circulation. Mobilization typically uses granulocyte colony-stimulating factor (G-CSF) administered subcutaneously for four to five days before collection. For autologous donors, chemotherapy plus G-CSF enhances mobilization.
Collection occurs via apheresis, processing large blood volumes to concentrate CD34+ cells. PBSC grafts provide faster neutrophil and platelet engraftment compared to bone marrow. However, higher T-cell content may increase chronic GVHD risk in allogeneic transplant.
Umbilical Cord Blood
Cord blood is collected from the placenta and umbilical cord after delivery. Units are cryopreserved in public or private cord blood banks. Advantages include immediate availability, reduced HLA matching stringency due to immunologic naivety, and lower GVHD rates despite HLA disparity.
Limitations include fixed cell dose potentially insufficient for larger recipients, delayed engraftment, and increased infection risk during prolonged neutropenia. Double cord blood transplantation using two partially matched units addresses cell dose limitations for adult recipients.
Finished reading?
Lock it in with a quick Foundations of Transplant quiz.